BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 7745719)

  • 1. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.
    Siebelink KH; Tijhaar E; Huisman RC; Huisman W; de Ronde A; Darby IH; Francis MJ; Rimmelzwaan GF; Osterhaus AD
    J Virol; 1995 Jun; 69(6):3704-11. PubMed ID: 7745719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection.
    Huisman W; Karlas JA; Siebelink KH; Huisman RC; de Ronde A; Francis MJ; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 1998; 16(2-3):181-7. PubMed ID: 9607028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.
    Tijhaar EJ; Huisman W; Huisman RC; Siebelink KH; Karlas JA; de Ronde A; van Herwijnen R; Mooi FR; Osterhaus AD
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3265-75. PubMed ID: 9400977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.
    Lombardi S; Garzelli C; Pistello M; Massi C; Matteucci D; Baldinotti F; Cammarota G; da Prato L; Bandecchi P; Tozzini F
    J Virol; 1994 Dec; 68(12):8374-9. PubMed ID: 7966629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
    Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
    Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
    Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
    J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
    Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.
    Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA
    Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats.
    Huisman W; Schrauwen EJ; Pas SD; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2008 May; 26(21):2553-61. PubMed ID: 18430494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus.
    Gonin P; Fournier A; Oualikene W; Moraillon A; Eloit M
    Vet Microbiol; 1995 Aug; 45(4):393-401. PubMed ID: 7483252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.
    Richardson J; Moraillon A; Baud S; Cuisinier AM; Sonigo P; Pancino G
    J Virol; 1997 Dec; 71(12):9640-9. PubMed ID: 9371628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.
    Flynn JN; Cannon CA; Neil JC; Jarrett O
    J Virol; 1997 Oct; 71(10):7586-92. PubMed ID: 9311839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
    Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
    AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats.
    Huisman W; Schrauwen EJA; Pas SD; Karlas JA; Rimmelzwaan GF; Osterhaus ADME
    J Gen Virol; 2004 Jul; 85(Pt 7):1833-1841. PubMed ID: 15218167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats.
    Burkhard MJ; Valenski L; Leavell S; Dean GA; Tompkins WA
    Vaccine; 2002 Dec; 21(3-4):258-68. PubMed ID: 12450701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against feline immunodeficiency virus using fixed infected cells.
    Verschoor EJ; van Vliet AL; Egberink HF; Hesselink W; van Alphen WE; Joosten I; Boog CJ; Horzinek MC; de Ronde A
    Vet Immunol Immunopathol; 1995 May; 46(1-2):139-49. PubMed ID: 7618254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement after feline immunodeficiency virus vaccination.
    Hosie MJ; Osborne R; Reid G; Neil JC; Jarrett O
    Vet Immunol Immunopathol; 1992 Dec; 35(1-2):191-7. PubMed ID: 1337397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
    Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
    Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.